PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018).
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
11
08
2020
accepted:
24
08
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
1
10
2020
Statut:
epublish
Résumé
•PIVOTALboost evaluates benefits/toxicity of pelvic node RT and focal boost dose escalation.•Unfavourable intermediate/high risk and bulky local disease are most likely to benefit.•Functional MRI imaging is used to select patients for different types of dose escalation.•HDR brachytherapy or focal dose escalation with IMRT are used as options.•Training and support is provided to reduce variations of contouring and radiotherapy planning.•The trial is recruiting patients in 38 radiotherapy centres through the UK.
Identifiants
pubmed: 32995575
doi: 10.1016/j.ctro.2020.08.003
pii: S2405-6308(20)30069-0
pmc: PMC7508714
doi:
Types de publication
Journal Article
Langues
eng
Pagination
22-28Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):386-92
pubmed: 19427741
J Clin Oncol. 2016 Jul 10;34(20):2325-32
pubmed: 27044935
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1376-84
pubmed: 21680108
Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):715-724
pubmed: 31812718
Nat Rev Clin Oncol. 2014 Jun;11(6):308-23
pubmed: 24840073
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):679-85
pubmed: 22954770
Radiat Oncol. 2012 Jan 30;7:14
pubmed: 22289620
Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):390
pubmed: 32386739
Lancet Oncol. 2018 Nov;19(11):1504-1515
pubmed: 30316827
Prostate Cancer Prostatic Dis. 2019 Sep;22(3):385-390
pubmed: 31363165
Radiother Oncol. 2012 May;103(2):217-22
pubmed: 22341794
BJU Int. 2017 Nov;120(5B):E87-E95
pubmed: 28464446
Clin Oncol (R Coll Radiol). 2017 Jan;29(1):6-14
pubmed: 27692920
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):605-617
pubmed: 30528653
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Nat Rev Urol. 2019 Sep;16(9):523-538
pubmed: 31346291
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):363-70
pubmed: 21195875
Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):759-769
pubmed: 27788949
Clin Oncol (R Coll Radiol). 2016 Oct;28(10):e139-47
pubmed: 27369458
Br J Cancer. 2018 Aug;119(4):389-407
pubmed: 30061587
Urology. 2000 Dec 20;56(6):899-905
pubmed: 11113727
Radiother Oncol. 2018 Apr;127(1):74-80
pubmed: 29336835
J Urol. 1992 Nov;148(5):1549-57; discussion 1564
pubmed: 1279218
Dig Dis Sci. 1988 Feb;33(2):129-34
pubmed: 3123181
Int J Impot Res. 1999 Dec;11(6):319-26
pubmed: 10637462
J Clin Oncol. 2017 Jun 10;35(17):1884-1890
pubmed: 28296582
Clin Radiol. 2015 Nov;70(11):1165-76
pubmed: 26231470
Lancet Oncol. 2016 Aug;17(8):1061-1069
pubmed: 27339116